Cas:733757-77-2 tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate

CAS.NO:733757-77-2

Synonyms:tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate

Molecular Formula:C₁₂H₁₉N₃O₂

Molecular Weight:237.29800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:58.22000

Exact Mass:237.14800

LogP:1.94920

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate Use and application,tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate technical grade,usp/ep/jp grade.

Related News: The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate manufacturer Lilly has denied retaliating against any employees, and no lawsuit has been filed on behalf of Mula. tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate vendor With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce. tert-butyl 3-methyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate factory At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.